Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study

Jeppesen, P B, Pertkiewicz, M, Forbes, A, Pironi, L, Gabe, S M, Joly, F, Messing, B, Loth, S, Youssef, N N, Heinze, H and Berghöfer, P (2013) Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study. Clinical Nutrition, 32 (5). pp. 713-21. ISSN 0261-5614

Full text not available from this repository. (Request a copy)

Abstract

Short bowel syndrome (SBS)-intestinal failure (IF) patients have impaired quality of life (QoL) and suffer from the burden of malabsorption and parenteral support (PS). A phase III study demonstrated that treatment with teduglutide, a glucagon-like peptide 2 analogue, reduces PS volumes by 32% while maintaining oral fluid intake constant; placebo-treated patients had reduced PS by 21%, but oral fluid intake increased accordingly. As effects of teduglutide on QoL are unknown, they were investigated here.

Item Type: Article
Additional Information: Copyright © 2013 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.
Uncontrolled Keywords: adult,aged,cost of illness,double-blind method,drinking,drug resistance,gastrointestinal agents,glucagon-like peptide 2,humans,injections, subcutaneous,intestinal diseases,intestine, small,middle aged,organ dysfunction scores,organ size,parenteral nutrition, home,peptides,quality of life,receptors, glucagon,short bowel syndrome
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: Pure Connector
Date Deposited: 06 Aug 2014 11:48
Last Modified: 11 Apr 2019 15:42
URI: https://ueaeprints.uea.ac.uk/id/eprint/49795
DOI: 10.1016/j.clnu.2013.03.016

Actions (login required)

View Item